CN103360276A - Crystal form, preparation method and application of agomelatine, as well as medicine composition - Google Patents
Crystal form, preparation method and application of agomelatine, as well as medicine composition Download PDFInfo
- Publication number
- CN103360276A CN103360276A CN2012100895296A CN201210089529A CN103360276A CN 103360276 A CN103360276 A CN 103360276A CN 2012100895296 A CN2012100895296 A CN 2012100895296A CN 201210089529 A CN201210089529 A CN 201210089529A CN 103360276 A CN103360276 A CN 103360276A
- Authority
- CN
- China
- Prior art keywords
- agomelatine
- crystal formation
- preparation
- chloroform
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 229960002629 agomelatine Drugs 0.000 title claims abstract description 78
- 239000013078 crystal Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 39
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 14
- 238000001953 recrystallisation Methods 0.000 claims description 14
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 239000012065 filter cake Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000000967 suction filtration Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 5
- 229960003987 melatonin Drugs 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000027559 Appetite disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010033664 Panic attack Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 210000002249 digestive system Anatomy 0.000 claims description 3
- -1 drageeing Substances 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 239000007972 injectable composition Substances 0.000 claims description 3
- 231100000863 loss of memory Toxicity 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 208000024714 major depressive disease Diseases 0.000 claims description 3
- 201000003995 melancholia Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000012672 seasonal affective disease Diseases 0.000 claims description 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 3
- 239000006190 sub-lingual tablet Substances 0.000 claims description 3
- 229940098466 sublingual tablet Drugs 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013456 study Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001519 thymoleptic effect Effects 0.000 description 2
- OQRMWUNUKVUHQO-UHFFFAOYSA-N 2-naphthalen-1-ylacetonitrile Chemical compound C1=CC=C2C(CC#N)=CC=CC2=C1 OQRMWUNUKVUHQO-UHFFFAOYSA-N 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- UUXLZQRTGHEMET-UHFFFAOYSA-N COC1=CC=C2C=CC=C(C2=C1)CCNC(C)=O.C(C)(=O)N Chemical compound COC1=CC=C2C=CC=C(C2=C1)CCNC(C)=O.C(C)(=O)N UUXLZQRTGHEMET-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- 229940121723 Melatonin receptor agonist Drugs 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- XURZGOTTZHKXTQ-UHFFFAOYSA-N acetonitrile;lithium Chemical compound [Li].CC#N XURZGOTTZHKXTQ-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000005260 alpha ray Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010316 high energy milling Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210089529.6A CN103360276B (en) | 2012-03-29 | 2012-03-29 | Crystal form, preparation method and application of agomelatine, as well as medicine composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210089529.6A CN103360276B (en) | 2012-03-29 | 2012-03-29 | Crystal form, preparation method and application of agomelatine, as well as medicine composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103360276A true CN103360276A (en) | 2013-10-23 |
CN103360276B CN103360276B (en) | 2015-02-18 |
Family
ID=49362632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210089529.6A Expired - Fee Related CN103360276B (en) | 2012-03-29 | 2012-03-29 | Crystal form, preparation method and application of agomelatine, as well as medicine composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103360276B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101735091A (en) * | 2009-12-30 | 2010-06-16 | 北京德众万全药物技术开发有限公司 | Preparation method of Agomelatine |
CN101792400A (en) * | 2010-03-16 | 2010-08-04 | 华东师范大学 | Synthetic method for agomelatine |
CN102050755A (en) * | 2009-10-29 | 2011-05-11 | 重庆医药工业研究院有限责任公司 | Novel agomelatine crystal forms and preparation methods of agomelatine crystal forms |
-
2012
- 2012-03-29 CN CN201210089529.6A patent/CN103360276B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102050755A (en) * | 2009-10-29 | 2011-05-11 | 重庆医药工业研究院有限责任公司 | Novel agomelatine crystal forms and preparation methods of agomelatine crystal forms |
CN101735091A (en) * | 2009-12-30 | 2010-06-16 | 北京德众万全药物技术开发有限公司 | Preparation method of Agomelatine |
CN101792400A (en) * | 2010-03-16 | 2010-08-04 | 华东师范大学 | Synthetic method for agomelatine |
Also Published As
Publication number | Publication date |
---|---|
CN103360276B (en) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100448843C (en) | New crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
EP2474522B1 (en) | Agomelatine and pharmaceutical compositions thereof | |
CN102716493B (en) | Copolymer containing amorphous agomelatine, and preparation method, pharmaceutical composition and application thereof | |
TW200936548A (en) | New crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
CN101585779A (en) | New crystal form of Agomelatine, preparation method and use thereof | |
EP2690087B1 (en) | New crystal form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same | |
HRP20040250A2 (en) | Crystals of hydroxynorephedrine derivative | |
AU2012231548B2 (en) | Mixed crystal agomelatine (Form-VIII), preparation method and use thereof and pharmaceutical composition containing same | |
CN102557979B (en) | Agomelatine crystal form, as well as preparation method, application and medicinal composition thereof | |
CN103360276B (en) | Crystal form, preparation method and application of agomelatine, as well as medicine composition | |
CN109476584A (en) | N- (2- (substitution-naphthalene -1- base) ethyl) substituted amide class compound, its preparation and application thereof | |
CN107698496A (en) | A kind of phthalic acid and the crystal formation of Etoricoxib forming salt and preparation method thereof | |
CN103690499B (en) | Stable crystalline form I agomelatine tablets and preparation method thereof | |
US12030867B2 (en) | Hsp90β selective inhibitors | |
US20210269418A1 (en) | Hsp90 beta selective inhibitors | |
NZ615714B2 (en) | Mixed crystalline form-VIII of agomelatine, its method of preparation, application and pharmaceutical use | |
NZ615707B2 (en) | New crystalline form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221025 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150218 |